Our Products

At Anvita, we specialize in high-quality Active Pharmaceutical Ingredients (APIs) tailored to address critical health needs in Indonesia and the ASEAN region. Our portfolio of small molecule APIs spans key therapeutic areas, including oncology, antivirals, diabetes, cardiovascular health, and more, supporting local resilience and improved access to essential medicines.

As a CDMO, Anvita not only supplies APIs but also develops ready-to-use drug formulations. Leveraging our expertise, we provide end-to-end solutions that accelerate product launch timelines for our partners.

Anvita’s portfolio focuses on high-prevalence conditions in Southeast Asia, offering new generic APIs for essential indications, such as:

Oncology (TKIs)
Imatinib, Nilotinib, Gefitinib

Antiviral and Anti-TB
Entecavir, Bedaquiline

Diabetes & Heart Failure
Sitagliptin, Dapagliflozin

Antihypertensive
Bisoprolol, Telmisartan, Candesartan

Antithrombotic
Rivaroxaban, Ticagrelor

Antigout
Febuxostat

Muscle Relaxants
Rocuronium, Sugammadex

Our product range reflects Anvita’s commitment to supporting the pharmaceutical industry with drug substance that drives the development of high-quality, effective treatments, strengthening healthcare resilience across Southeast Asia.

Our Facilities

Our state-of-the-art facility, located on a 25,000 sqm site within Karawang New Industrial City (KNIC), a world-class integrated industrial estate, houses both production and development capabilities. The facility features multiple advanced workshops for API manufacturing and drug formulations. Our comprehensive R&D center further supports our commitment to innovation, enabling us to continuously enhance product quality and develop new formulations so we can better support our partners.

PT Anvita Pharma Indonesia
Karawang New Industry City
Blok B No. 8
Karawang, Indonesia